CliffBio
small molecule

SANDOSTATIN

OCTREOTIDE ACETATE

Loss of exclusivity—loss of exclusivity
CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand nameSANDOSTATIN
Active ingredientOCTREOTIDE ACETATE
StrengthEQ 1MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalJune 1991
Marketing statusDISCN

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.